Tests Impacted by 2015 CPT Changes
|
|
|
- Nigel Ross
- 8 years ago
- Views:
Transcription
1 Toxicology Changes for 2015 HPV Examples of Toxicology Panels Molecular Pathology, FISH and Anatomic Pathology 1
2 Toxicology Changes for Test Code Dos Test Name Medicare 5229 Drug Screen, Comprehensive, with Confirmation, Serum 80301, 80329, 80345, G Drug Screen, Comprehensive, with 6640 Drug Screen, Comprehensive, with, Serum Drug Screen, Comprehensive, without Confirmation, Gastric Drug Screen, Comprehensive, with Confirmation, Serum,, Gastric 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, , 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, 80377, 80301, 80329, 80345, , 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, , 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, 80377, 80301, 80329, 80345, , 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, G0431 G0431 x2 G0431 G0431 x NonSteroidal Anti Inflammatory Drug Panel G Drug Test, General Toxicology, Blood Drug Test, General Toxicology, 80320, 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, , 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, G0431 G0431 2
3 Test Code Dos Test Name Medicare Drug Test, General Toxicology, Serum 80320, 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, G Comprehensive Blood Tox Screen 80345, 80329, 80346, G Substance Abuse Panel 7 plus Heroin and LSD with 80361, 80323, 80349, 83992, 80326, 80345, 80346, 80361, G Test Code Dos Test Name Medicare 451 Drug Screen Panel 1, Meconium 453 Drug Screen Panel 4, Meconium 454 Drug Screen Panel 5, Meconium 463 Drug Screen Panel 2, Meconium 649 Drug Abuse Panel 6-20, Special 855 Strychnine Screen Strychnine Screen, blood Drug Screen, Clinical 1 without Confirmation, Serum 1094 Substance Abuse Panel 7 with 1262 Substance Abuse Panel 8-50 with 2124 Drug Abuse Panel 10-20, without Confirmation 2125 Drug Abuse Panel Ethanol, No Confirmation 80329, 80320,, 82003, 80196,
4 Test Code Dos Test Name Medicare 2126 Drug Abuse Panel with Confirmation, 2127 Drug Abuse Panel with Confirmation, 2128 Alcohol, Ethyl, Qualitative, with 2130 Drug Abuse Panel Plus Ethanol without 2158 Marijuana Metabolites-20 Screen with Confirmation 2179 Drug Abuse Panel Plus Ethanol 2180 Drug Abuse Panel Plus Ethanol with 2593 Substance Abuse Panel plus Ethanol with 2595 Substance Abuse Panel 9 with Confirmation, Special, 3023 Substance Abuse Panel with 3111 Oxycodone, Qualitative, without 3120 Drugs of Abuse Screen (11 Panel), Fluid 3154 Heroin Screen 3198 Acetaminophen Screen G Antihistamines Screen G Levorphanol (Screen) G Substance Abuse Panel 7-50 GC/MS 6065 Butorphanol Screen, Free (Unconjugated) Cocaine Metabolites, Qualitative, /Gastric 6093 Cocaine Metabolites, Qualitative, GC/MS,
5 Test Code Dos Test Name Medicare 6103 Dextromethorphan, Qualitative, or Gastric 6126 Ethchlorvynol, Qualitative, /Gastric 6176 LSD Screen Meclizine Screen Meperidine, Qualitative, Random Methadone, Qualitative, GC/MS, Methaqualone, Qualitative, GC/MS, Phencyclidine, Qualitative, GC/MS, Phenothiazines, Qualitative, Propoxyphene, Qualitative, GC/MS, Marijuana Metabolites-15 by GC/MS, Qualitative, Substance Abuse Panel GC/MS 6403 Substance Abuse Panel 6-50 with Confirmation 6404 Substance Abuse Panel 5-50 GC/MS 6405 Substance Abuse Panel 5-50 GC/MS 6406 Substance Abuse Panel 7-50, GC/MS, 6440 Substance Abuse Panel 10-20, GC/MS Confirmation 6581 Substance Abuse Panel Substance Abuse Panel 7 GC/MS 6633 Substance Abuse Panel with 6636 Substance Abuse Panel 6-50 GC/MS 7170 Amphetamines Screen with Confirmation, 5
6 Test Code Dos Test Name Medicare 7171 Barbiturates Screen, with Confirmation, 7172 Benzodiazepines Screen with Confirmation, 7173 Cocaine Metabolites Screen with 7174 Marijuana Metabolites-50 Screen, with 7176 Methadone Screen with Confirmation 7177 Methaqualone Screen with Confirmation, 7178 Marijuana Metabolites-100 Screen with Confirmation 7179 Opiate Metabolites Screen with 7180 Phencyclidine Screen with Confirmation 7181 Propoxyphene Screen with Confirmation 7182 Substance Abuse Panel 2-50, GC/MS 7375 Substance Abuse Panel 10 with 7376 Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel 8-50 with Confirmation 7908 Substance Abuse Panel Volatiles, Qualitative, G Substance Abuse Panel Drug Abuse Panel without 6
7 Test Code Dos Test Name Medicare 8255 Drug Abuse Panel 9-50, without 8262 Drug Abuse Panel 6-50 without 8300 Antidepressant Panel 1, 80337, LSD Screen, G Methylenedioxymethamphetamine (MDMA) Antihistamine Panel Antihistamine Panel, LSD Screen, Blood Ketamine and Metabolite Screen Ketamine and Metabolite Screen, Drug Screen, Clinical 1, without Oxycodone Screen and Nicotine Metabolite Screen G Tox 7 Screen, Opiates Clinical Screen, without Drug Abuse Panel Drug Abuse Panel 8-20 with Confirmation, Drug Abuse Panel 7-20 with Confirmation, Opiates, Qualitative, GC/MS, Benzodiazepines, Qualitative, GC/MS, Barbiturates, Qualitative, GC/MS, Drug Abuse Panel 7-20 with Confirmation, 7
8 Test Code Dos Test Name Medicare Confirmed Infant Drug Abuse Screen #3, Meconium Drug Abuse Panel 7-50 with Confirmation, Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel 8-50 with Confirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel Drug Abuse Panel with Confirmation, Drug Abuse Panel 7 with Confirmation, Drug Abuse Panel 5-50 without Amphetamines (1000 ng/ml Screen), without Cocaine Metabolites Clinical Screen, without Methadone Clinical Screen, without Drug Abuse Panel without Cinfirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel 6-100, without Opiates Clinical Screen with Confirmation Drug Abuse Panel 6-50 with Confirmation, 8
9 Test Code Dos Test Name Medicare Drug Abuse Panel 5-20 with Confirmation, Drug Abuse Panel 8-50 without Drug Abuse Panel without Drug Abuse Panel 4-50 without Drug Abuse Panel 7-50 with Confirmation, Drug Abuse Panel without Drug Abuse Panel Amphetamine Screen with Confirmation, Serum Amphetamine Screen, with Confirmation, Amphetamine Screen with Confirmation, Blood Drug Abuse Panel with Drug Abuse Panel with Confirmation, Drug Abuse Panel 4-50 without 80324, G , , Monoacetylmorphine, Qualitative, Volatiles, Marijuana Metabolites-20 Clinical Screen with Confirmation Alcohol, Ethyl, Qualitative, Barbiturates Clinical Screen, with Propoxyphene Clinical Screen with Confirmation 9
10 Test Code Dos Test Name Medicare Marijuana Metabolites-100 Clinical Screen with Confirmation Amphetamines-1000 Clinical Screen, with Cocaine Metabolites Clinical Screen, with Phencyclidine Clinical Screen, with Opiates Metabolites, GC/MS, 80361, G Substance Abuse Panel 9-50 Plus Ethanol with Progressive Drug Screen # Substance Abuse Panel 8-50 plus Ethanol with Drug Abuse Panel (Refl) Tox 10 Profile, THC 20, with Alcohol, Tox 10 Screen with Alcohol, Tox 8 Profile with Tox 8 Screen, Toxicology 10 Profile, THC-50, Tox 10 Screen, THC-50, Tox 10 Profile, THC 20, Tox 10 Screen, THC 20, Benzodiazepines, Qualitative, GC/MS, Tox 9 Profile with Tox 9 Screen, Alcohol, Ethyl, Qualitative, without Pain Management, Buprenorphine, without 10
11 Test Code Dos Test Name Medicare DAP 5-50, SemiI Quant w/thc Creatiine Ratio, No Confirm Drug Abuse Panel 8-50 with Confirmation, 80301, G Pain Management Base Profile with Pain Management Base Profile without 80301, 82570, 83986, , 82570, 83986, G0431 G Buprenorphine Screen, with Quantitative Buprenorphine, Qualitative, Drug Panel Plus Ethanol with Drug Abuse Panel 6-50, with Confirmation, Fentanyl Screen with Reflex Confirmation G Pain Management Profile 1 with Confirmation, without medmatch, Pain Management Profile 2 with Confirmation, without medmatch, Pain Management Profile 3 with Confirmation, without medmatch, Pain Management Base Profile with Confirmation, without medmatch, Pain Management Profile 4 with Pain Management Profile 4 with Confirmation, without medmatch, Pain Management Profile 4 without 80301, 82570, 83986, , 82570, 83986, , 82570, 83986, , 82570, 83986, , 82570, 83986, , 82570, 83986, , 82570, 83986, G0431 G0431 G0431 G0431 G0431 G0431 G Drug Abuse Panel 9-50 Plus Ethanol without Drug Abuse Panel 5 without Confirmation, 11
12 Test Code Dos Test Name Medicare Drug Abuse Panel 5-50 without Drug Abuse Panel 6-50 Plus Ethanol without Drug Abuse Screen 6 with Confirmation Drug Abuse Panel 8 without Confirmation, Benzodiazepines, Qualitative, GC/MS, Opiates 5, Qualitative, 80361, Pain Management Profile 2 with Pain Management Profile 2 without Pain Management Profile 3 with Pain Management Profile 3 without Pain Management Profile 1 with Pain Management Profile 1 without 80301, 82570, 84311, , 82570, 84311, , 82570, 84311, , 82570, 84311, , 82570, 84311, , 82570, 83986, G0431 G0431 G0431 G0431 G0431 G Phencyclidine, Qualitative, GC/MS, Marijuana, Qualitative, GCMS, Pain Management, Amphetamines, with Pain Management, Barbiturates, with Pain Management, Benzodiazepines, with Pain Management, Cocaine Metabolite, with Pain Management, Marijuana Metabolite, with G
13 Test Code Dos Test Name Medicare Pain Management, Methadone, with Pain Management, Opiates, with Pain Management, Oxycodone, with Pain Management, Phencyclidine, with Pain Management, Propoxyphene, with Pain Management, Buprenorphine, with Pain Management, MDMA/MDA, with Pain Management, Alcohol Metabolites, with Pain Management, Heroin Metabolite, with Drug Abuse Panel 5-50 with THC Quantitative G Fentanyl, Progressive G Barbiturate Presumptive Screen Drug Abuse Panel 6-50 without Drug Abuse Panel 9, No Confirmation Drug Abuse Panel 5-50, No Confirmation Drug Abuse Panel 4 without Confirmation, Drug Abuse Panel 9-50, without Drug Panel 8 (no THC), with Confirmation, Pain Management, Marijuana Metabolite, with Confirmation, with medmatch, 13
14 Test Code Dos Test Name Medicare Pain Management, Methadone, with Confirmation, with medmatch, Pain Management, Opiates, with Confirmation, with medmatch, Pain Management, Oxycodone, with Confirmation, with medmatch, Pain Management, Phencyclidine, with Confirmation, with medmatch, Pain Management, Propoxyphene, with Confirmation, with medmatch, G Drug and Alcohol Screen Buprenorphine and Metabolite Screen Buprenorphine and Metabolite Screen, Blood Opiate Metabolites Screen with Confirmation Substance Abuse Panel 8-50 Plus Ethanol with Oxycodone and Metabolite, with Quantitative Drug Screen, Pain 1 with Confirmation, Drug Screen 1 with Fentanyl Presumptive Screen, G Marijuana Metabolites-50 Clinical Screen with Confirmation Oxycodone, with Qualitative Confirmation, Oxycodone, with Quantitative Confirmation, with confirm code with confirm code80365 G0434 G Hypoglycemic Panel, Qualitative Drug Panel 6, Quantitative, 14
15 Test Code Dos Test Name Medicare Drug Panel , Quantitative with Ethyl Alcohol, Drug Panel 10-50, Quantitative, Drug Panel 10, Quantitative, Tramadol Screen with Reflex to G Drug Panel 10-50, Quantitative, Drug Abuse Panel 9, Serum Drug Abuse Screen 5 without Confirmation, Serum Drug Abuse Screen 7 with Confirmation, Serum Opiates, Progressive Drug Abuse Panel Alfentanil Screen, Drug Abuse Panel with Confirmation, Drug Abuse Panel Plus Ethanol with Drug Abuse Panel 9-50 with Confirmation, Drug Abuse Panel 9-50 with Confirmation, Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel Ethanol Drug Abuse Panel 9-50 Plus Ethanol with Drug Abuse Panel 6-50 with Confirmation, 15
16 Test Code Dos Test Name Medicare Drug Abuse Panel 6-50 with Confirmation, Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel Ethanol Drug Abuse Panel 6-50 Plus Ethanol, Drug Abuse Panel 5-50 without Drug Abuse Panel Drug Abuse Panel 5-50 with Confirmation, Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel 5-50 Plus Ethanol with Confirmations, Drug Abuse Panel 5-50 Plus Ethanol with Confirmations, Drug Abuse Panel Drug Abuse Panel Ethanol Drug Abuse Panel 9-20, No Confirmation Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel 9-20 Plus Ethanol without Drug Abuse Panel 9-20 Plus Ethanol with Drug Abuse Panel Ethanol Drug Abuse Panel 6-20, No Confirmation Drug Abuse Panel 6-20 with Confirmation, Drug Abuse Panel
17 Test Code Dos Test Name Medicare Drug Abuse Panel 6-20 Plus Ethanol without Drug Abuse Panel Ethanol Drug Abuse Panel Ethanol Nalbuphine Screen Free (Unconjugated) G Antidepressant Panel , G Cocaine and Metabolites Screen, Blood Cocaine and Metabolites Screen Marijuana Metabolites-100 Clinical Screen with Confirmation Marijuana Metabolites (THC 50 ng/ml) Clinical Screen with Confirmation Marijuana Metabolites (THC 20 ng/ml) Clinical Screen with Confirmation Drug Abuse Panel Plus Ethanol with Drug Abuse Panel 10 with Confirmation, Drug Abuse Panel 10, No Confirmation Naltrexone and Metabolite Screen, Free (Unconjugated) Substance Abuse Panel with Creatinine , G Drug Screen Panel 9, Meconium Drug Abuse Panel Plus Ethanol without Drug Abuse Panel 9 + Ethanol Drug Abuse Panel 9 + Ethanol Drug Abuse Panel Drug Abuse Panel 10 Plus Ethanol 17
18 Test Code Dos Test Name Medicare Amphetamines (1000 ng/ml Screen), with Barbiturates Clinical Screen, with Benzodiazepines Clinical Screen, with Cocaine Metabolites Clinical Screen, with Methadone Clinical Screen, with Methaqualone Clinical Screen, with Opiates Clinical Screen, with Confirmation, Phencyclidine Clinical Screen with Propoxyphene Clinical Screen, with Substance Abuse Panel 6-50 with Opiates, Substance Abuse Panel 10 with Opiates, Substance Abuse Panel with Opiates, Ipecac Use Markers G Marijuana Metabolites-100 No Confirmation Antidepressant Panel /Gastric, Qualitative Drug Abuse Panel 3-50, without Drug Abuse Panel 8-20, Volatiles, Qualitative, Gastric Marijuana Metabolites-50 No Confirmation 18
19 Test Code Dos Test Name Medicare Drug Abuse Panel 9-50, without Drug Abuse Panel with Confirmation, (Refl) Cannabinoids Panel, Cocaine and Metabolite Screen with Confirmation, Meconium Phencyclidine Screen Drug Abuse Panel (Refl) without Confirmation Drug Abuse Panel 7-50, No Confirmation Drug Abuse Panel 8-50, No Confirmation Drug Abuse Panel 7-50, No Confirmation Drug Abuse Panel 5-50 without Drug Abuse Panel 5-50 without Drug Abuse Panel 6-50 without Drug Abuse Panel 8-50, No Confirmation Benzodiazepines, without Confirmation, Drug Abuse Panel plus Ethanol without Confirmation Drug Abuse Panel 5, No Confirmation Alprazolam and Metabolite Screen Triazolam and Metabolite Screen Drug Abuse Panel 4 without Confirmation, Methamphetamine /Gastric Qualitative LSD Presumptive Screen G
20 Test Code Dos Test Name Medicare Drug Abuse Panel Benzodiazepines Screen Gamma-Hydroxybutyric Acid Screen, Gamma-Hydroxybutyric Acid Screen Drugs of Abuse Screen, Serum And Volatiles Drug Abuse Panel 8-50 Plus Ethanol without Drugs Of Abuse Screen, Serum Sports I Expanded Barbiturates, without Drug Abuse Panel 3-20 with Confirmation, (Refl) Drug Abuse Panel 6 without Confirmation, Drug Abuse Panel 7-50 without Confirmation Drug Abuse Panel 6-50 Plus Ethanol without Drug Abuse Panel Ethanol (Refl) Drug Abuse Panel 8-50, No Confirmation Buprenorphine, Qualitative, without Oxycodone and Metabolite (100), Qualitative, GC/MS, Cocaine Metabolite-100, Qualitative, GC/MS, Methadone and Metabolite (100), Qualitative, GC/MS, Opiates, Expanded (100), Qualitative, GC/MS,
21 Test Code Dos Test Name Medicare Pain Management, Amphetamines, with Confirmation, with medmatch, Pain Management, Barbiturates, with Confirmation, with medmatch, Pain Management, Benzodiazepines, with Confirmation, with medmatch, Pain Management, Cocaine Metabolite, with Confirmation, with medmatch, Pain Management, Buprenorphine, with Confirmation, with medmatch, Work Comp, Base Profile with Confirmation, Pain Management, MDMA/MDA, with Confirmation, with medmatch, Pain Management, Alcohol Metabolites, with Confirmation, with medmatch, Pain Management, Heroin Metabolite, with Confirmation, with medmatch, G Work Comp, Profile 1 with Confirmation, Pain Management Profile 5 with Confirmation, without medmatch, Pain Management Profile 5 without Pain Management Profile 5 with 80301, 82570, 84311, 83986, 80301, 82570, 83986, , 82570, 84311, , 82570, 84311, G0434 G0431 G0431 G Ethyl Glucuronide with Carisoprodol Screen G Phencyclidine Clinical Screen, without Propoxyphene Clinical Screen, without Carisoprodol Screen with Reflex Confirmation G
22 Test Code Dos Test Name Medicare Oxycodone, Qualitative without (REFL) Drug Abuse Panel 9-50 No Confirm (Refl) Synthetic Cannabinoid Metabolites Screen, Expanded, Synthetic Cannabinoid Metabolites Screen, Drug Abuse Panel w meth150, eddp, noconf MDMA/MDA Screen with Confirmation, G G Synthetic Cannabinoids, Qualitative, Blood Synthetic Stimulants, Qualitative, Synthetic Stimulants, Qualitative, Serum Synthetic Stimulants, Qualitative, Blood Synthetic Cannabinoids, Qualitative, Synthetic Cannabinoids, Qualitative, Serum Oxycodone, with Qualitative Confirmation, Synthetic Cannabinoid Panel 1, Synthetic Cannabinoid Panel 2, Drug Toxicology Monitoring 1 with Drug Toxicology Monitoring 2 with Drug Toxicology Monitoring 3 with Drug Toxicology Monitoring 4 with Drug Toxicology Monitoring 5 with G G G G G
23 Test Code Dos Test Name Medicare Drug Toxicology Monitoring 6 with Drug Toxicology Monitoring 7 with Drug Toxicology Monitoring 8 with Drug Toxicology Monitoring 9 with G G G G Drug Toxicology Monitoring 1 Screen, G Drug Toxicology Monitoring 2 Screen, G Drug Toxicology Monitoring 3 Screen, G Drug Toxicology Monitoring 4 Screen, G Drug Toxicology Monitoring 5 Screen, G Drug Toxicology Monitoring 6 Screen, G Drug Toxicology Monitoring 7 Screen, G Drug Toxicology Monitoring 8 Screen, G Drug Toxicology Monitoring 9 Screen, G Drug Toxicology Monitoring, Amphetamines, with Drug Toxicology Monitoring Barbiturates, with Drug Toxicology Monitoring Benzodiazepines, with Drug Toxicology Monitoring Buprenorphine, with Drug Toxicology Monitoring Cocaine Metabolite, with Drug Toxicology Monitoring Alcohol, Ethyl, with Drug Toxicology Monitoring Heroin Metabolite, with G
24 Test Code Dos Test Name Medicare Drug Toxicology Monitoring Marijuana Metabolite 20, with Drug Toxicology Monitoring Marijuana Metabolite 50, with Drug Toxicology Monitoring MDMA, with Drug Toxicology Monitoring Methadone Metabolite, with Drug Toxicology Monitoring Opiates, with Drug Toxicology Monitoring Oxycodone, with Drug Toxicology Monitoring Phencyclidine, with Drug Toxicology Monitoring Propoxyphene, with Drug Toxicology Monitoring Amphetamines, Screen, Drug Toxicology Monitoring Barbiturates, Screen, Drug Toxicology Monitoring Benzodiazepines, Screen, Drug Toxicology Monitoring Buprenorphine, Screen, Drug Toxicology Monitoring Cocaine Metabolite, Screen, Drug Toxicology Monitoring Alcohol, Ethyl, Screen, Drug Toxicology Monitoring Opiates, Screen, Pain Management, Amphetamines, No Pain Management, Benzodiazepines, No Pain Management, Benzodiazepines, No G G G G
25 Test Code Dos Test Name Medicare Pain Management, Cocaine Metabolite, No Pain Management, Heroin Metabolite, No Pain Management, Marijuana Metabolite, No Pain Management, MDMA, No Pain Management, Methadone, No Pain Management, Opiates, No Pain Management, Oxycodone, No Pain Management, Phencyclidine, No Pain Management, Propoxyphene, No Drug Toxicology Monitoring Heroin Metabolite, Screen, Drug Tox Monitoring, Methadone Metabolite, Screen, U G Drug Toxi Monitoring, Opiates, Screen, U G Drug Toxicology Monitoring Oxycodone, Screen, Drug Toxicology Monitoring Phencyclidine Screen, Pain Management Profile 1 with Confirmation, with D/L Isomers, Pain Management Profile 1 with Confirmation, with D/L Isomers, without medmatch, 80301, 82570, 84311, , 82570, 84311, G0434 G Diuretics Screen, Psilocybin as Psilocin, Qualtitative,
26 Test Code Dos Test Name Medicare Marijuana Metabolite-50 with Creatinine Ratio, without Confirmation 80301, G Acetyl Fentanyl, Qualitative, Acetyl Fentanyl, Qualitative, Blood Acetyl Fentanyl, Qualitative, Serum Drug Screen Panel 1, Meconium 453 Drug Screen Panel 4, Meconium 454 Drug Screen Panel 5, Meconium 463 Drug Screen Panel 2, Meconium 649 Drug Abuse Panel 6-20, Special 855 Strychnine Screen Strychnine Screen, blood Drug Screen, Clinical 1 without Confirmation, Serum 1094 Substance Abuse Panel 7 with 1262 Substance Abuse Panel 8-50 with 2124 Drug Abuse Panel 10-20, without Confirmation 2125 Drug Abuse Panel Ethanol, No Confirmation 2126 Drug Abuse Panel with Confirmation, 80329, 80320,, 82003, 80196,
27 Oxycodone, Qualitative, GC/MS, G Amphetamines (200), Qualitative Confirmation, GC/MS, Oxycodone and Metabolite (100), QL, GCMS, Phencyclidine, Confirm by GC/MS, Meconium 80324, G G G Cannabinoids Panel G Cocaine and Metabolites Qual, Hair G DS13, No Confirm G Express Cup Drug Panel w/o Confirm, G Clonazepam G Chlordiazepoxide G Diazepam G Halazepam as Metabolite G
28 3139 Midazolam, Blood G Alprazolam (Xanax) G Temazepam and Oxazepam G Midazolam G Nitrazepam G Benzodiazepines, Quantitative, GC/MS, G Diazepam, Quantitative G Benzodiazepine, GC/MS, G Midazolam as Metabolite, G Pain Management, Benzodiazepines, Quantitative, Pain Management, Clonazepam Metabolite, Quantitative, Flunitrazepam and Metabolites, Quantitative, G G G Flunitrazepam and Metabolites, Quantitative G Benzodiazepines Panel, Blood G Clobazam G Alprazolam, Quantitative, G Lorazepam () G Lorazepam G Benzodiazepines G Clonazepam and 7-amino Clonazepam, G Diazepam G Rohypnol, G Rohypnol, Serum G
29 59436 Clonazepam and Metabolite G Benzodiazepines, Serum G Pain Management, Benzodiazepines, Quantitative, with medmatch, Pain Management, Clonazepam Metabolite, Quantitative, with medmatch, G G Benzodiazepines, Quantitative, G Benzodiazepines, Quantitative, GC/MS, G Diazepam and Metabolite G Clorazepate (Tranxene ) G Oxazepam G Desipramine G Imipramine G Valproic Acid, Total and Free 80164, , Valproic Acid, Free
30 Doxepin G Gold, G Gold G Imipramine G Imipramine G Nortriptyline G Amitriptyline G Pain Management, Tricyclic Antidepressants, Quantitative, with medmatch, Pain management, Tricyclic Antidepress, QN, G6037, G G6037, G
31 Salicylate G Percodan, blood 80329, G Ethosuximide Paramethadione Phenylpropanolamine Phensuximide Phenylbutazone and Metabolite Chloral Hydrate Halazepam as Metabolite Midazolam (B) Naproxen (Blood) Trazodone () Phenazopyridine Scopolamine () Primidone, Phenobarbital and PEMA 80339, 80345, , 80188, Trazodone Naproxen Ibuprofen Phenacemide
32 5389 Pemoline Cyclobenzaprine Dimethylsulfoxide (Blood) Mescaline, Methocarbamol, Serum/Plasma Phenelzine Pseudoephedrine Tolmetin Tranylcypromine Sulfate Zomepirac Orphenadrine Sertraline Citalopram Tramadol and Metabolit Zolpidem Ketamine and Metabolite Coricidin G6039, Dextro/Levo Methorphan, Escitalopram Escitalopram, Aripiprazole, Blood Aripiprazole, Quantitative Rufinamide Quetiapine, Blood
33 16823 Duloxetine Ziprasidone Pregabalin Pregabalin, Quantitative, Paroxetine Mephenytoin and Metabolite Maprotiline Protriptyline (Vivactil ) Chloral Hydrate, Blood Piroxicam (Feldene) Diclofenac (Voltaren) Nefazodone (Serzone) Mirtazapine (Remeron) Fluvoxamine (Luvox) Thiothixene (CIS Isomer) Loxapine Quetiapine, Serum or Plasma Oxycarbazepine Metabolite Baclofen, Serum/Plasma Dextro/Levo Methorphan Doxepin Methsuximide Ritalin Rohypnol,
34 59356 Rohypnol, Serum Olanzapine Tapentadol, Free Zolpidem, Quantitation, Cyclobenzaprine, Paliperidone Methylphenidate Metabolite, Quantitative, Ethosuximide Paramethadione Phenylpropanolamine Acetaldehyde (B) Acetonitrile Exposure Profile, Blood 82491, 82010, , 82010, Acetaminophen G Darvocet 80329, G6039, G Fioricet, 80371, 80345, G6039, 80155, G Fioricet, Blood 80329, 80155, G6039, 80155, G Fioricet, Tissue 80329, 80155, G6039, 80155, G
35 8313 Fioricet, Fluid 80329, 80155, G6039, 80155, G Fioricet serum/plasma 80329, 80155, G6039, 80155, G Coricidin G6039, Acetaminophen Confirmation G Alcohol, Ethyl, Blood G Alcohol, Ethyl, Blood G Alcohol, Ethyl, Quantitative, Random G Drug Toxicology Monitoring Alcohol Ethyl, Quant, G Alcohol, Ethyl (U), QN G Alcohol, Ethyl, Enzymatic G Amphetamines, Quantitative, GC/MS, G Amphetamines (D/L Ratio), Blood G Amphetamines (D/L Ratio) G Amphetamines (D/L Ratio), G
36 3384 Selegiline and Metabolites Amphetamines Panel, Blood 80326, G Phentermine G Pemoline Amphetamine, Confirmation, GC/MS, Serum G MDMA and Metabolite G Amphetamine Confirmation by GC/MS, Serum Amphetamine Confirmation by GC/MS, 80359, G , G Amphetamine Confirmation, GC/MS, Blood 80359, G % Amphetamines Confirmation, Fluid G Pain Management, Amphetamines, Quantitative, G MDMA/MDA, Quantitative, G Methamphetamine Isomers, D and L G Methamphetamine and Amphetamine (B) G Amphetamines Panel, Serum 80326, G Amphetamines Confirmation, GC/MS, Meconium G Amphetamines G Pain Management, Amphetamines, Quantitative, with medmatch, Pain MGMT, Methamphetamine D/L Isomers, urine Pain Management, MDMA/MDA, Quantitative, Pain Management, MDMA/MDA, Quantitative, with medmatch, G G G G
37 91539 Drug Tox Monitoring Amphetamines, QN, Drug Toxicology Monitoring MDMA, Quantitative, G G Methamphetamine and Metabolite, G Drug Toxicology Amphetamines, Quantitative, Oral Fluid Drug Toxicology MDMA, Quantitative, Oral Fluid G G Pain Management Amphetamines with D/L Isomers, Quantitative, Pain Management Amphetamines with D/L Isomers, Quantitative, w medmatch Pain Management, Methamphetamine D/L Isomers, G G G Amobarbital G Metharbital and Metabolite G Pentobarbital G Secobarbital G Barbiturates Panel, Blood G Butalbital G Thiopental and Metabolite G Barbiturates, Quantitative GC/MS Confirmation, Serum G Barbiturates, GC/MS, G
38 8568 Barbiturates, G Mephobarbital and Metabolite G Pain Management, Barbiturates, Quantitative, G Barbiturates G Pain Management, Barbiturates, Quantitative, with medmatch, G Barbiturates Panel, G Drug Toxicology Monitoring Barbiturates, Quantitative, Drug Toxicology Barbiturates, Quantitative, Oral Fluid G G Amobarbital G Metharbital and Metabolite G Pentobarbital G Methsuximide as Metabolite / Carisoprodol and Metabolite Phenylbutazone and Metabolite Trimethadione and Metabolite Clozapine Phenobarbital, Free/Bound
39 6017 Allopurinol and Metabolite Mephenytoin and Metabolite Marijuana Metabolite, Quantitative, Amoxapine and Metabolite Inhalants Panel, Blood (CSA) 84600, Inhalants Panel, (CSA) 84600, Amiodarone OR Carisoprodol and Metabolite Cocaine and Metabolites Qualitative, Hair G Cocaine Metabolites, GC/MS, G Cocaine, Confirmation by GC/MS G Pain Management, Cocaine Metabolite, Quantitative, Cocaine, Confirmation by GC/MS, Meconium G G Cocaine G Work Comp, verify, cocaine metabolite qn, u G Pain Management, Cocaine Metabolite, Quantitative, with medmatch, Drug Toxicology Monitoring Cocaine Metabolite, Quantitative, Drug Toxicology Cocaine, Quantitative, Oral Fluid G G G Cocaine and Metabolites Qualitative, Hair G
40 Methaqualone (Quaalude ) Marijuana Metabolites, GC/MS, Methaqualone, GC/MS, Cannabinoids Ketamine and Metabolite LSD, Quantitative, GC/MS, THC Confirmation, GC/MS with Ratio 80349, Pain Management, Marijuana Metabolite, Quantitative, Cannabinoids Panel marijuana metabolites, quantitative, LSD Trace Analysis (U) LSD Trace Analysis Cannabinoids Panel Qualitative, Meconium Marijuana Confirmation, GC/MS, Meconium Cannabinoids Confirmation, Meconium Baclofen (Lioresal ) Pain Management, Tramadol, Quantitative, with medmatch, Pain Management, Marijuana Metabolite, Quantitative, with medmatch, Drug Toxicology Monitoring Marijuana Metabolite, Quantitative,
41 Hydrocodone and Metabolites, Tissue G Hydrocodone and Metabolites, Fluid G Hydrocodone and Metabolite, G Hydrocodone G Hydrocodone and Metabolite, Serum G Hydromorphone G Dihydrotestosterone, Free, Serum G Dihydrotestosterone, LC/MS/MS G Dihydrotestosterone, Free, Serum G Trimethadione and Metabolite G Dimethadione G
42 Ethchlorvynol G Flurazepam and Metabolites G Glutethimide Carisoprodol and metabolite G Meprobamate G Meprobamate G Pain Mgmt, Carisoprodol Metabolit, QN, Drug Tox Monitoring Carisoprodol Met, QN, U G G Drug Tox Meprobamate, QN, Oral Fluid G
43 Clozapine Alcohol Metabolites, Quant, Risperidone Selegiline & Metabolites Fluoxetine Bupropion and Metabolite, Serum or Plasma Sertraline and Desmethylsertraline, Serum/Plasma Tramadol and Metabolite LSD Confirmation Carisoprodol and Metabolite, Pain Management, Alcohol metab, qn, urine Pain Management, Alcohol metab, qn, urine Venlafaxine and Metabolite Pain Management, Gabapentin, QN, Pain Management, Tramadol, Quantitative, Pain Management, Pregabalin, Quantitative, Clomipramine LSD Trace Analysis, LSD Trace Analysis Diuretic Panel S/P Carbamazepine-10,11-Epoxide Sildenafil and Metabolite
44 70208 Pain Management, Pregabalin, Quantitative, with medmatch, Pain Management, Tapentadol, Quantitative, Pain Management, Tapentadol, Quantitative, with medmatch, Pain Management, Methylphenidate Metabolite, Quantitative, Pain Management, Methylphenidate Metabolite, Quantitative, with medmatch, Pain Management, Synthetic Stimulants Quantitative, with medmatch, Pain Management, Synthetic Stimulants, Quantitative, MDPV Stimulant Designer Drug Test MDPV Stimulant Designer Drug Test, Tapentadol, Quantitative, Bath Salts Panel, Blood Bath Salts Panel, Serum/Plasma Drug Toxicology Monitoring, Tramadol, Quantitative, Drug Toxicology Zolpidem, Quantitative, Oral Fluid Drug Toxicology Marijuana, Quantitative, Oral Fluid Synthetic Stimulants
45 Methsuximide as Metabolite G Methadone G Methadone, GC/MS, G METHADONE BY GC/MS, NCOC G Methadone and Metabolite, G Pain Management, Methadone, Quantitative, Pain Management, Methadone, Quantitative, with medmatch, G G Work Comp, Verify, Methadone, QN, U G Drug Toxicology Monitoring Methadone Metabolite, Quantitative, Drug Toxicology Methadone, Quantitative, Oral Fluid G G Nicotine, Serum G Nicotine and Metabolite, Fluid G Nicotine and Cotinine, LC/MS/MS G Nicotine and Cotinine, LC/MS/MS, G
46 90982 Nicotine and Expanded Metabolites, LC/MS/MS, Nicotine and Expanded Metabolites, LC/MS/MS Drug Toxicology Nicotine, Quantitative, Oral Fluid G G G Codeine and Metabolite (Unconjugated) G Darvocet 80329, G6056, G Morphine G Opiates, GC/MS, G Pentazocine G Percodan 80329, G6056, G Propoxyphene, GC/MS, G Oxycodone and Metabolite, GC/MS, G Opiates Metabolites by gcms 80361, G Opiates 2000, GC/MS, G Opiates, Expanded by GC/MS, 80361, G Opiate Confirmation by GCMS, 80361, G Pain Management, Buprenorphine, Quantitative, Pain Management, Opiates Expanded, Quantitative, G , G Buprenorphine, Quantitative, G Pain Management, Fentanyl, Quantitative, G
47 16905 Pain Management, Meperidine, Quantitative, Pain Management, Oxycodone, Quantitative, Pain Management, Propoxyphene Metabolite, Quantitative, Oxycodone and Metabolite, Quantitative, G G G G Meperidine, GC/MS, G Fentanyl and Norfentanyl, G Morphine, Quantitative, G Fentanyl and Metabolite, Blood G Oxycodone and Metabolite, Quantitative G Heroin Metabolites, Quantitative, 80361, G Opiates Confirmation, Enhanced Sensitivity, Pain Management, Fentanyl, Quantitative, with medmatch, Pain Management, Buprenorphine, Quantitative, with medmatch, 80361, G G G Monoacetylmorphine, GC/MS, G Opiate Confirmation, GC/MS 80361, G Opiates, Expanded by GC/MS () 80361, G Opiates 5, Quantitative, 80361, G Oxycodone Free (Unconjugated) G Opiates, Serum 80361, 80365, G Meperidine G Propoxyphene, Quantitative, GC/MS, Serum G Oxycodone Confirmation, GC/MS, G
48 37449 Morphine (Free and Total) G Opiates Confirmation, GC/MS, Meconium 80361, G Fentanyl and Norfentanyl G Meperidine and Normeperidine, G Pain Management, Meperidine, Quantitative, with medmatch, Pain Management, Opiates Expanded, Quantitative, with medmatch, Pain Management, Oxycodone, Quantitative, with medmatch, Pain Management, Propoxyphene Metabolite, Quantitative, with medmatch, Pain Management, Heroin Metabolite, Quantitative, Pain Management, Heroin Metabolite, Quantitative, with medmatch, G , G G G G G Naloxone, Quantitative, G Buprenorphine and Naloxone, LC/MS/MS 80348, G Drug Toxicology Monitoring Buprenorphine, Quantitative, Drug Toxicology Monitoring Fentanyl, Quantitative, Drug Toxicology Monitoring Heroin Metabolite, Quantitative, Drug Toxicology Monitoring Opiates, Quantitative, Drug Toxicology Monitoring Oxycodone, Quantitative, Drug Toxicology Monitoring Propoxyphene, Quantitative, Drug Toxicology Monitoring Tapentadol, Quantitative, G G G G G G G
49 91602 Drug Toxicology Monitoring Opiates Expanded, Quantitative, 80361, G Opiates Confirmation, LC/MS/MS 80361, G Codeine and Metabolite (Unconjugated) G Darvocet 80329, G6056, G Trifluoperazine G Chlorpromazine G Promethazine G Mesoridazine G Thioridazine and Metabolite G Thiothixene (CIS Isomer) G Perphenazine G Mellaril G Fluphenazine, Serum or Plasma G Fluphenazine G Trifluoperazine G Chlorpromazine G Promethazine G
50 Alcohol, Isopropyl, Blood Alcohol, Methyl, Blood Volatiles Inhalants Panel, Blood 84600, Hydrocarbon and Oxygenated Volatiles Panel 84600, Methanol, Inhalants and Metabolites Panel, 84600, Isopropanol/Acetone Volatiles with ethylene glycol 84600,
51 Examples of Toxicology Panels Test Code Dos Test Name Tricyclic Antidepressant Panel (3) Pain Management, Tricyclic Antidepressants, Quantitative, Tricyclic Antidepressants ID and Quantitation Tricyclic Antidepressant Evaluation Antidepressant Panel, 80337, 80338, Antidepressant Panel, Blood 80337, 80338, Antidepressant Panel 80337, 80338, Antidepressant Panel Drug Toxicology Monitoring 1, Quantitative, Oral Fluid 80324, 80345, 80346, 80353, 80349, 80359, 80369, 80358, 80323, 80348, 80361, 80354, 80356, 80362, 80365, 80367, 80372, 80373, 83992, Drug Toxicology Opioids, Quantitative, Oral Fluid 80348, 80354, 80361, 80365, 80356, 80367, 80362, 80372, Pain Management Profile 1 with Confirm, 80301, 82570, 83986, Pain Management Profile 1 with Confirm,, w D/L Isomers 80301, 82570, 83986, Pain Management Profile 2 with Confirm, 80301, 82570, 83986, Pain Management Profile 4 with Confirm, 80301, 82570, 83986, Pain Management Profile 5 with Confirm,, w D/L Isomers 80301, 82570, 83986, reflex Pain Management Profile 6 with Confirm, 80301, 82570, 83986, Pain Management Profile 7 with Confirm, 80301, 82570, 83986, Pain Management Profile 1 with Confirm,, w/o Medmatch 80301, 82570, 83986, Pain Management Profile 1 with Confirm,, w D/L Isomers w/o Medmatch Pain Management Profile 1 with Confirm,, w D/L Isomers w/o Medmatch 80301, 82570, 83986, reflex , 82570, 83986, reflex
52 Test Code Dos Test Name Pain Management Profile 2 with Confirm, w/o Medmatch 80301, 82570, 83986, Pain Management Profile 4 with Confirm, w/o Medmatch 80301, 82570, 83986, Pain Management Profile 5 with Confirm,, w D/L Isomers w/o Medmatch 80301, 82570, 83986, reflex Pain Management Profile 6 with Confirm, w/o Medmatch 80301, 82570, 83986, Pain Management Profile 7 with Confirm, w/o Medmatch 80301, 82570, 83986, Pain Management Profile 1 without Confirm, 80301, 82570, 83986, Pain Management Profile 2 without Confirm, 80301, 82570, 83986, Pain Management Profile 4 without Confirm, 80301, 82570, 83986, Drug Tox Monitoring 9 with Drug Tox Monitoring 9 Screen, Pain Management Profile 8 with Confirm, 80301, 82570, 83986, Pain Management Profile 8 with Confirm, w/o Medmatch 80301, 82570, 83986,
53 HPV Test Code Dos Test Name HPV (Human Papillomavirus) DNA, High Risk, Anal-Rectal HPV DNA, High Risk HPV DNA, High Risk HPV DNA, High Risk with Reflex to Genotypes 16, reflex to HPV DNA, High Risk with Reflex to HPV Genotypes 16, reflex to HPV DNA, Low and High Risk HPV DNA, Low and High Risk with Reflex to Genotypes 16, reflex to HPV DNA, Low and High Risk, Anal-Rectal HPV Genotype HPV Genotypes 16, HPV Genotypes 16, 18/ HPV mrna E6/E HPV mrna E6/E7 with Reflex to HPV Genotypes 16, 18/ with reflex to HPV mrna E6/E7, Rectal HPV, High Risk, Hybrid Capture II with Reflex 16, reflex to OraRisk HPV SurePath Imaging Pap (REFL) HPV mrna E6/E7 reflex HPV 16,18/ (HCPCS: G0145), reflex to SurePath Imaging Pap and HPV mrna E6/E7 reflex HPV 16,18/ (HCPCS: G0145), with reflex to SurePath Imaging Pap and HPV mrna E6/E7, C. trachomatis, N. gonorrhoeae or 88175; HCPCS: G0144 or G0145; , SurePath Imaging Pap with Reflex to HPV mrna E6/E or 88175; HCPCS: G0144 or G0145 reflex to SurePath Imaging Pap with Reflex to HPV mrna E6/E7, C. trachomatis, N. gonorrhoeae or 88175; HCPCS: G0144 or G0145; 87491, with reflex to SurePath Imaging Pap (Refl) HPV DNA Low and High Risk (HCPCS: G0145) with reflex to
54 Test Code Dos Test Name SurePath Imaging Pap (RL) HPV mrna E6/E (HCPCS: G0145) with reflex to SurePath Pap (Refl) HPV DNA High/Low Risk 87624, SurePath Pap and HPV mrna E6/E , (HCPCS: G0123) SurePath Pap and HPV mrna E6/E7 reflex HPV 16,18/ , (HCPCS: G0123) with reflex to SurePath Pap and HPV mrna E6/E7, C. trachomatis, N. gonorrhoeae 87491, 87591, 87624, (HCPCS: G1023) SurePath Pap with Reflex to HPV mrna E6/E ; HCPCS: G0123 with reflex to SurePath Pap with Reflex to HPV mrna E6/E7, C. trachomatis, N. gonorrhoeae 87491, 87591, (HCPCS: G0123) with reflex to SurePath Imaging Pap and HPV mrna E6/E (HCPCS: G0145), SurePath -FP (Refl) HPV DNA High/Low Risk (HCPCS: G0145) with reflex to ThinPrep Pap reflex HPV DNA and C. trachomatis, N. gonorrhoeae (HCPCS: G0123), 87491, with reflex to ThinPrep Pap reflex HPV mrna E6/E7, C. trachomatis, N. gonorrhoeae (HCPCS: G1023), 87491, with reflex ThinPrep Imaging Pap (Refl) ThinPrep Imaging Pap (Refl) HPV DNA reflex HPV 16, or (HCPCS: G0144 or G0145) with reflex to with possible reflex to ThinPrep Imaging Pap and HPV DNA or (HCPCS: G0144 or G0145), ThinPrep Imaging Pap and HR HPV DNA reflex HPV 16, or (HCPCS: G0144 or G0145), with reflex to ThinPrep Imaging Pap and HR HPV DNA, C. trachomatis, N. gonorrhoeae ThinPrep Imaging Pap and HPV mrna E6/E7 reflex HPV 16,18/45 with CT/NG ThinPrep Imaging Pap and HPV mrna E6/E7, with CT/NG, Trichomonas or (HCPCS: G0144 or G0145), 87491, 87591, , 87624, 87491, with reflex to , 87624, 87491, 87591, ThinPrep Imaging Pap reflex HPV DNA or (HCPCS: G0144 or G0145) with reflex to
Toxicology CPT Code Changes for 2016
Beginning January 1, 2016, CMS deleted all 2015 drug testing G codes and will continue to not recognize the AMA CPT codes for drug testing. CMS created three G codes for presumptive testing and four G
The CPT code for Human papillomavirus (HPV) has changed from 87621 to 87624. This code (87624) covers testing for HPV High Risk genotypes.
January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) Coding Manual on an annual basis. For 2015, the AMA made several
An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse
Drug Testing An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse Printed on August 18, 2016 1:59 pm CST 2016 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.
DUI in Southern Ohio MATT 2006
DUI in Southern Ohio MATT 2006 Laureen J. Marinetti, M.S., Ph.D. Chief Toxicologist Montgomery County Coroner s s Office & Miami Valley Regional Crime Lab (MVRCL) Dayton, Ohio Region The MVRCL is a regional
Oral Fluid Drug Testing March 23 rd, 2015
Oral Fluid Drug Testing March 23 rd, 2015 Drug Testing Options Breath Blood Meconium Vitreous Hair Sweat Urine Oral Drug Testing Options Oral Fluid and Blood and Breath Actual levels (immediate use, up
2015 CPT Code Changes ACL Test
Changes ACL Test Test Description UCOMP DRUG SCREEN COMPLETE 80100 80303 G0431 UDINV DRUG INVESTIGATION 80100 80303 G0431 UTLC THIN LAYER CHROMATOGRAPHY DRUG SCREEN 80100 80303 G0431 UNIC NICOTINE, URINE
June 2016 Updated Crosswalk:
June 2016 Updated Crosswalk: 2016 HCPCS G0279 G6001 G6002 G6003 G6004 deleted f Radiology Coding BCBSNC currently considers this service investigational and will not cover either the HCPCS CPT s. Diagnostic
Urine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA
Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives Describe what chronic pain is, who is affected and
Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine
Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine Application Note Authors Peter JW Stone and Kevin McCann Agilent Technologies, Inc. Santa Clara,
Pain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
PtProtect Pain Medication Management Program Monitors Patient Compliance
PHYSICIAN UPDATE 2013 Edition PtProtect Pain Medication Management Program Monitors Patient Compliance The PtProtect (Patient Protect) program offers pain medication management panels designed to improve
2013 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS
Toxicology Program Trends 213 213 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS Overview and Background This report discusses trends in the toxicology program, as well as the number of toxicology
SMART DISCHARGE. Client s Name: Client ID: Partial Hospitalization Clinically Managed Medium Intensity Residential Treatment
SMART DISCHARGE Client s Name: Client ID: DATE OF DISCHARGE: Reason for Discharge Completed Treatment no further treatment needed Completed Treatment Plan/Referred Incomplete Client Left Before Completing
Urine drug screens. Screening Methods
Screening Methods Urine drug screens Urine drug screens are generally performed using either immunoassays or gas chromatography-mass spectrometry (GC-MS). 2 Immunoassay UDS contain specific antibodies
LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
LC-MS for Pain Management Support
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)
Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently
What Does the Drug Test Tell Us
What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background The qualitative drug test is often referred to as the drug screen - a misnomer Testing performed
Clinical Drug Screening and/or Drug Testing
Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 1/8/2016
Oral Fluid as an alternative matrix in workplace drug testing: which drugs at which cutoff concentration?
Oral Fluid as an alternative matrix in workplace drug testing: which drugs at which cutoff concentration? Michael Böttcher MVZ Labor Dessau Gmb, Dessau, Germany a d d i c t i o n / a b u s e r e l e v
Changes to CPT Coding for 2015
Changes to CPT Coding for 2015 The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) coding manual on an annual basis. For 2015, the pathology and laboratory section
TRENDS IN ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES IN MELBOURNE 2009 10
AMBO PROJECT: ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES TRENDS IN ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES IN MELBOURNE 2009 10 Belinda Lloyd ambo project: Alcohol and Drug Related Ambulance
PSYCHOSOMATIC INSTITUTE OF SAN ANTONIO New Patient Information
PSYCHOSOMATIC INSTITUTE OF SAN ANTONIO New Patient Information Name: Last: First: MI: Birth Date: Sex: M F Marital Status: Single Married Divorced Separated Widowed Partnered Other Preferred name: Emergency
Clinic Reference Guide
Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40
CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003
Page 1 ATTACHMENT C CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003 PURPOSE This policy provides guidelines for the detection and deterrence of alcohol and drug
Early Morning Waking Excessively Orderly or Perfectionistic
COLLEGE OF MEDICINE Jacksonville 580 W 8 th St T-2 6 th Fl Ste 6005 6266 Dupont Station Ct Department of Psychiatry Jacksonville, FL 32209 Jacksonville, Fl 32217 Division of Adult Psychiatry Phone 904-383-1038
Psychiatric Medications: Pearls and Pitfalls. The majority of medications used in patients with psychiatric diagnoses have more than one use.
Psychiatric Medications: Pearls and Pitfalls Rule #1 The majority of medications used in patients with psychiatric diagnoses have more than one use. Without access to the patient s medical record, to review
2013 Annual Toxicology Report
213 Annual Toxicology Report Department of Justice Forensic Science Division Toxicology Department 2679 Palmer Street Missoula, MT 5988 DOJTOX@mt.gov Personnel Phil Kinsey Scott Larson Scott Schlueter
Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method
Simultaneous Quantitation of 4 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method Xiang He and Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 76 Key Words TSQ Quantum Access
12629 LIBRIUM CHLORDIAZEPOXIDE HCL 12637 LIBRIUM CHLORDIAZEPOXIDE HCL 12645 LIBRIUM CHLORDIAZEPOXIDE HCL 13110 VALIUM DIAZEPAM 13277 VALIUM DIAZEPAM 24406 LITHANE LITHIUM CARBONATE 25836 SURMONTIL TRIMIPRAMINE
Update on Drug Impaired Driving. WTSC Impaired Driver Conference SeaTac, December 2006
Update on Drug Impaired Driving WTSC Impaired Driver Conference SeaTac, December 2006 12/4/2007 Alcohol, Drugs and Driving Household Survey, 2004 (prior year) Any Illicit Drug Use 19.9 Million 8.3% Marijuana
Collection Instructions for ARUP Drug Screen Kit #49204
Collection Instructions for ARUP Drug Screen Kit #49204 Manufacturer Purpose of Kit / Reagent (tests) Kit / Reagent Contents (list components) Other Supplies Needed ARUP Laboratories For Point of Collection
1. Carrying Personal Medications into Thailand A. Medications containing narcotic drugs of category 2
Guidance for Travellers to Thailand under Treatment Carrying Personal Medications Containing Narcotic Drugs/Psychotropic Substances into/out of Thailand This guidance issued by the Narcotics Control Division,
Indiana State Department of Toxicology 2012 Annual Report
Indiana State Department of Toxicology 2012 Annual Report Pictured on the cover is the State of Indiana Forensic and Health Sciences Laboratories facility housing the Indiana State Department of Toxicology.
Drug Testing in the Pain Management Setting
Drug Testing in the Pain Management Setting September 27, 2011 Gwen McMillin, PhD, DABCC University of Utah, ARUP Laboratories Disclosure Laboratory director consultant for Clinical Lab Consulting, LLC
Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment
Clinical Position Statement Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment CLINICAL POSITION STATEMENT In most cases, immunoassay (qualitative) drug testing is sufficient for
What Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse
Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse Grant D. Beardsley, M.S., MT(ASCP) Clinical Toxicologist, Grant Beardsley, MS, MT(ASCP) I have nothing to disclose. I
Simultaneous Quantitation of 78 Drugs and Metabolites in Urine with a Dilute-And-Shoot LC MS-MS Assay
Journal of Analytical Toxicology 2015;1 12 doi:10.1093/jat/bkv024 Journal of Analytical Toxicology Advance Access published April 1, 2015 Article Simultaneous Quantitation of 78 Drugs and Metabolites in
Understanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011
Understanding Drug Screens & PharmCAS Drug Screening Program Overview Suzi Arant, Senior Business Developer July 8, 2011 Presentation Overview Drug Screening in Healthcare Drug Screening Panels Drugs of
MVP s Medicare Stars Ratings: High Risk Medications
MVP s Medicare Stars Ratings: High Risk Medications The Center for Medicare and Medicaid Services (CMS) uses the Star Rating System to evaluate Medicare Advantage health plans as well as their networks
Drugs with Anticholinergic Activity
PL Detail-Document #271206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER December 2011 Drugs with Anticholinergic
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers Important Notes: Last Updated: May 11, 2015 Pharmacists must submit a claim on PharmaNet at the time of purchase to enable coverage.
FLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013. 2012 Report
FLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013 2012 Report Data Collection The Office of Vital Statistics reported more than 178,000 deaths occurred in Florida during 2012. Of these, the medical
Emit Drugs of Abuse Urine Assays Cross-Reactivity List. Answers for life.
Emit Drugs of Abuse Urine Assays Cross-Reactivity List Answers for life. Contents Emit II Plus Amphetamines...4 Emit II Plus Barbiturate...8 Emit II Plus Benzodiazepine... 12 Emit II Plus Cannabinoid...
A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System
A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System Kent Johnson Fortes lab, Wilsonville Oregon List of drug of abuse candidates for
OU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol
OU MEDICAL CENTER Human Resource Policy and Procedure Manual Subject: Drug and Alcohol Section: HR 6-10 Page: 1 of 5 Origination Date: 6/2004 Revision Date: 2/2006, 9/2008, 7/2009 Coverage: All OUMC employees
Triage TOX Drug Screen Product Insert Rapid Qualitative simultaneous detection of drug and/or the major urinary metabolites of 10 different drug
Triage TOX Drug Screen Product Insert Rapid Qualitative simultaneous detection of drug and/or the major urinary metabolites of 10 different drug classes (11 unique assays). Product Insert Catalog#: 94400
SCID-I (for DSM-IV-TR) Alcohol Abuse (JAN 2010) Substance Use Disorders E. 2
SCID-I (for DSM-IV-TR) Alcohol Abuse (JAN 2010) Substance Use Disorders E. 2 *LIFETIME ALCOHOL ABUSE* IF DEFINITE PERIOD: Let me ask you a few more questions about (TIME WHEN DRINKING THE MOST OR HAD PROBLEMS).
Drug Utilization Is On The Rise
Objectives Identify the clinical issues related to opioid prescribing for chronic pain indications Define the clinical needs and expectations of urine drug testing in pain management Address preanalytical
YOUR MEDICATIONS WHAT YOU SHOULD KNOW
YOUR MEDICATIONS WHAT YOU SHOULD KNOW A Handbook For People With Developmental Disabilities Developmental Disabilities Area Board 10 Developmental Disabilities Area Board 10 411 N. Central Avenue Suite
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
Appropriate utilization of drug tests for pain management patients
Appropriate utilization of drug tests for pain management patients Gwen McMillin, PhD, DABCC (CC, TC) Medical Director, Toxicology, ARUP Laboratories Associate Professor (clinical), University of Utah
Utility of Oral Fluid in Compliance Monitoring of Opioid Medications
Pain Physician 2014; 17:63-70 ISSN 1533-3159 Prospective Evaluation Utility of Oral Fluid in Compliance Monitoring of Opioid Medications Till Conermann, MD, Ankur R. Gosalia, MD, Abraham Jack Kabazie,
PROFILE -V MEDTOXScan Drugs of Abuse Test System INSERT
PROFILE -V MEDTOXScan Drugs of Abuse Test System INSERT 1. INTENDED USE The PROFILE -V MEDTOXScan Drugs of Abuse Test System consists of the PROFILE -V MEDTOXScan Test Devices and the MEDTOXScan Reader.
Neurotransmitters Made Easy: The Mood Teeter-Totter
Neurotransmitters Made Easy: The Mood Brad Lander PhD, LICDC Clinical Director / Psychologist Talbot Hall - Addiction Medicine at The Ohio State University Wexner Medical Center Key Point #1 Thinking and
The DRE DUI & DRUGS. Captain George Crum Fullerton Police Department
The DRE DUI & DRUGS Captain George Crum Fullerton Police Department What is a DRE? Drug Recognition Expert Experienced officer Selected by their department Special training in detecting drug influence/impairment
Amy LaHood MD MPH FAAFP December 19, 2012
Amy LaHood MD MPH FAAFP December 19, 2012 Identify trends & consequences of the current opioid epidemic Review evidence & expert guidelines for prescribing controlled substances Identify challenges/solutions
DRUG DRIVING OFFENCES
DRUG DRIVING OFFENCES Taking drug can affect body and mind coordination that can significantly impair the ability to drive a motor vehicle. Road Traffic Ordinance (Cap 374) was amended in 2011 in order
The potential of oral fluid as a specimen in various drug testing programs
The potential of oral fluid as a specimen in various drug testing programs *Christine Moore, Cynthia Coulter, Katherine Crompton, Warren Rodrigues, Michael Vincent, James Soares Immunalysis Corporation,
Drug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005
DOT/FAA/AM-08/10 Office of Aerospace Medicine Washington, DC 20591 Drug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005 Sabra R. Botch
The Effects Of Drug Abuse On Dialysis
DRUGS OF ABUSE IN THE DIALYSIS POPULATION 2 0 1 4 H E A R T L A N D K I D N E Y C O N F E R E N C E Jamie Killion, PharmD, BCPS MEDICAL I N FORMATION SPECIALIST OBJECTIVES: Describe the magnitude of drug
a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes einforcement
Drug Abuse (chapter 18) 1. Definitions iti a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes 2. Neural Mechanisms of Re einforcement a. mesolimbic dopamine system b.
Why do employers drug test? How is drug testing conducted and how accurate is it?
Workplace Drug Testing Drug testing is one action an employer can take to determine if employees or job applicants are using drugs. It can identify evidence of recent use of alcohol, prescription drugs
Substance Abuse Prevention and Treatment Agency 2012 Community Profile
Substance Abuse Prevention and Treatment Agency 2012 Community Profile Nevada Division of Mental Health and Developmental Services Department of Health and Human Services Brian Sandoval, Governor Michael
Clinical Drug Testing in Primary Care
Clinical Drug Testing in Primary Care Technical Assistance Publication Series TAP 32 Clinical Drug Testing in Primary Care TAP Technical Assistance Publication Series 32 U.S. DEPARTMENT OF HEALTH AND
Appropriate Use of UDT to Improve Patient Care
Published on OpioidRisk (http://www.opioidrisk.com) Home > Urine Drug Testing Urine Drug Testing This guide provides: Download Entire Guide [1] Appropriate use of Urine Drug Testing (UDT) to improve patient
South Carolina Drug Statutes South Carolina Code of Laws: Title 44 Health Code
SCHEDULE CRITERIA AND COMPOSITION SCHEDULE I: (a) A high potential for abuse; (b) No accepted medical use in treatment in the United States; (c) A lack of accepted safety for use in treatment under medical
PAYMENT POLICY STATEMENT
PAYMENT POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 01/01/2014 04/05/2017 04/05/2016 Policy Name Policy Number Drug Screening Tests PY-0020 Policy Type
Diagnostic Accuracy and Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach
Diagnostic Accuracy and Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach Amadeo Pesce 1, Cameron West 1, Kathy Egan-City 1 and William Clarke 2 2 1 Millennium Research
Urine Drug Testing Methadone 101 Methadone for hospitalists
Urine Drug Testing Methadone 101 Methadone for hospitalists Dr. Patricia Mark MB, BCh LEARNING OBJECTIVES Clarify the purpose of urine drug testing Distinguish between UDT for detection of illicit drug
punishment increased 1 degree. If force used, degree felony (3)(A) other opium and opiates Delivery of Penalty 1 Substance 180days-2yrs; <$10,000
PENALTY GROUP OFFENSES/PENALTIES ENHANCEMENTS/BENEFIT RESTRICTIONS 481.102 Penalty Group 1 (1) Opiates (2) Opium derivatives: e.g., codeine compounds, morphine compounds, heroin 481.112 Manufacture or
Diagnostic Accuracy Study Protocol. Pain Physician 2010; 13:E1-E22 ISSN 2150-1149. www.painphysicianjournal.com
Pain Physician 2010; 13:E1-E22 ISSN 2150-1149 Diagnostic Accuracy Study Protocol Protocol for Accuracy of Point of Care (POC) or In-Office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective
Comparison of EMIT II, CEDIA and DPC RIA Assays for the Detection of Lysergic Acid Diethylamide in Forensic Urine Samples*
Journal of Analytical Toxicology, Vol, 26, October 2002 Comparison of EMIT II, CEDIA and DPC RIA Assays for the Detection of Lysergic Acid Diethylamide in Forensic Urine Samples* Russell F. Wiegand, Kevin
PRESCRIPTION DRUG ABUSE
PRESCRIPTION DRUG ABUSE Carl M. Dawson, M.S., MAC, LPC - National Drug Court Institute ( NDCI ) Washington, D. C. - The School of Professional Psychology at Forest Institute Springfield, Missouri ( cdawson1028@yahoo.com
Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications
Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with the sensitivity and selectivity
AppNote 6/2011. Determination of Pain Management Drugs using Automated Disposable Pipette Extraction and LC-MS/MS KEYWORDS ABSTRACT
AppNote 6/2011 Determination of Pain Management Drugs using Automated Disposable Pipette Extraction and LC-MS/MS Fred D. Foster, John R. Stuff, Edward A. Pfannkoch Gerstel, Inc., 701 Digital Dr. Suite
Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications
TECHNICAL NOTE Toxicology Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with
Disclosures Christer Allgulander
How Patients With Generalized Anxiety Disorder (GAD) Are Treated in Specialized Care: A Pharmacoepidemiological Case Register Study in Sweden Christer Allgulander MD, Karolinska Institutet, Sweden Jan
Urine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns
Urine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns Edward J. Cone* Johns Hopkins School of Medicine, Baltimore, Maryland Yale H. Caplan National Scientific Services, Baltimore,
Updated MAR 26, 2013 Myelography Seizures:
Updated MAR 26, 2013 Myelography Medications to be evaluated prior to myelography. This list is to assist the radiologist, pharmacist, and radiology technologist in evaluating medication risk associated
Serenity Psychiatry, LLC Mimi Armellino, DO Of Coastal Counseling Associates. Patient History Form
Serenity Psychiatry, LLC Mimi Armellino, DO Of Coastal Counseling Associates Patient History Form Name Date Age DOB SSN Address City State ZIP Patient s Telephone (H) (W) (Cell) Email Job Title or School
Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies
Downloaded from orbit.dtu.dk on: Nov 25, 2015 Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies Bernhoft, Inger Marie; Hels, Tove Publication
HELPING YOUR BUSINESS DO MORE Webinar Series
HELPING YOUR BUSINESS DO MORE Webinar Series The Employers Council of Iowa, the Greater Des Moines Partnership, Kaplan University and Iowa Works bring you a series of educational webinars. These webinars
Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
Clinical Chemistry / POC Testing f o r Dr u g s o f Ab u s e in t h e ED Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
Urine Drug Testing. Why drug test? Set the Standard!
Urine Drug Testing Urine drug testing is a valuable tool for the physician when making treatment decisions. Patients and physicians benefit from safe and effective treatment of pain but there are always
Opiates Heroin/Prescription Steve Hanson Opiates Dates to 4,000 BC Mimics endorphin activity Natural - Opium, morphine, codeine Semi-synthetic- Heroin, Dilaudid Synthetics - Darvon, Demerol, Fentanyl Modern
Lamictal, lamotrigine Lithium, lithobid, eskalith Depakote, valproate Trileptal, oxcarbazepine Tegretol, equetro, carbamazepine Atypicals (aripiprazole, abilify, olanzapine, zyprexa, invega, risperdal,
Improved Method for the Analysis of 31 Drugs of Abuse in Oral Fluid samples using the Thomson extreme FV by LC-MS/MS
htslabs.com folks@htslabs.com 800 541.4792 760 757.8080 760 757.9367 Improved Method for the Analysis of 31 Drugs of Abuse in Oral Fluid samples using the Thomson extreme FV by LC-MS/MS Nadine Koenig 2,
Prescription Drugs: Abuse and Addiction
EAP Drug Free Workplace Newsletter March 2014 Prescription Drugs: Abuse and Addiction What are some of the commonly abused prescription drugs? Although many prescription drugs can be abused or misused,
How To Understand The Health Effects Of Prescription Drugs
Miami-Dade, Broward and Palm Beach Counties, Florida Trends of Nonmedical Prescription Drug Misuse in Miami-Dade, Broward, Palm Beach Counties, and the State of Florida: 2010 James N. Hall 1 ABSTRACT The
PSYCHIATRIC MEDICATIONS AND HIV ANTIRETROVIRALS ADULT MANAGEMENT Winter 2013 ADRUGINTERACTIONGUIDEFORCLINICIANS
PSYCHIATRIC MEDICATIONS AND HIV ANTIRETROVIRALS ADULT MANAGEMENT Winter 2013 ADRUGINTERACTIONGUIDEFORCLINICIANS Psychiatric Medications and HIV Antiretrovirals: A Drug Interaction Guide for Clinicians
Monitoring Program (DMP) heroin purchase data (edited versions) were also utilized. Data were also obtained from the Threat Assessment Report
Drug Abuse Trends in the Seattle/King County Area: 2011 Caleb Banta-Green 1, T. Ron Jackson 2, Steve Freng 3, Michael Hanrahan 4, Geoff Miller 8, Steve Reid 5, John Ohta 6, Mary Taylor 7, Richard Harruff
Drug Testing: Answers to Frequently Asked Questions and New Drug Trends
Drug Testing: Answers to Frequently Asked Questions and New Drug Trends National TASC Conference May 9, 2013 Jaime Anderson TASC, Inc Copyright 2011, TASC Inc. Topics of Discussion Sample Media Comparison
Drugs & driving: the place of medication reviews in improving safety for older road users. Dr Jenny Gowan
Drugs & driving: the place of medication reviews in improving safety for older road users Dr Jenny Gowan Consultant pharmacist, Northern & North East Valley Divisions of General Practice, Melbourne, Victoria,
Hair Drug & Alcohol Testing FAQs
HAIR DRUG TESTING More than DNA Hair Drug & Alcohol Testing FAQs Need advice about testing? Contact us using our online SMS service or call Cellmark free on 0800 043 4247 2045 Introduction Cellmark is
West Virginia Department of Health and Human Resources Bureau for Public Health Office of Emergency Medical Services
OEMSI==o..-::::::- 9 ---- ~ West Virginia Controlled Substance Policy Statement This policy establishes the standard for the management of Controlled Substances by WV EMS agencies in accordance with Federal
Rapid Screening Method for Illicit Drugs, Using an Advanced Solid Core UHPLC Column and UHPLC System with MS/MS Detection
Rapid Screening Method for Illicit Drugs, Using an Advanced Solid Core UHPLC Column and UHPLC System with MS/MS Detection Derek Hillbeck, Thermo Fisher Scientific, Runcorn, UK Application Note 2999 Key
CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES
CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES Vina SPIEHLER 1, Dene BALDWIN 2, Christopher HAND 2 1 DABFT, Newport Beach, United States of America 2 Cozart
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion